Summit Therapeutics Files Prospectus for Potential Resale of 108.9M Shares

Summit Therapeutics filed a prospectus supplement for the potential resale of up to 108,955,369 shares of its common stock by a selling stockholder. The shares are issuable upon the conversion of existing preferred stock, and the company will not receive any proceeds from the sale of these shares.

Key Details

• Shares Offered: Up to 108,955,369 shares of common stock may be offered for resale from time to time by the selling stockholder.
• Source of Shares: The common stock is issuable upon the conversion of 108,955.3686 shares of Class A Convertible Preferred Stock held by the selling stockholder.
• Filing Details: The prospectus supplement, dated November 4, 2026, was filed under the company's automatic shelf registration statement on Form S-3 (Registration No. 333-296642).